Skip to content
Open access

Body composition assessment for risk stratification of hepatic steatosis in patients with type 2 diabetes and MASLD undergoing osteoporosis screening

Aug 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 53 references
Medicine

TL;DR

In patients with MASLD and T2D, DXA-derived body composition measures may complement conventional anthropometric assessment and help identify individuals with severe hepatic steatosis.

Abstract

Background and aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide. Type 2 diabetes (T2D) and obesity are major risk factors for its development and progression. Body mass index (BMI), although widely used in clinical practice, fails to adequately reflect individual differences in body composition and fat distribution. This study evaluated the association of adiposity and reduced muscle mass – measured by dual-energy X-ray absorptiometry (DXA) – with hepatic steatosis severity in patients with MASLD and T2D. Methods Consecutive patients with MASLD and T2D were recruited at a tertiary hepatology centre. Body composition was assessed by DXA. Adiposity was defined using fat mass percentage, with values >25% in men and >35% in women indicating obesity. Muscle mass was assessed using the appendicular lean mass/height2 (ALM/height²) index, with pathological values defined as <7.0 kg/m2 in men and <5.5 kg/m2 in women. Hepatic steatosis and fibrosis were evaluated by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. Statistical analyses included Spearman’s rank correlation, Chi Square test, logistic regression, and receiver operating characteristic (ROC) curve analyses. Results Ninety-seven patients (median age 61 years) were enrolled. DXA identified a pathological fat mass percentage in 97.9% of patients, whereas 46.4% met the BMI-based criteria for obesity. At multivariate analysis, fat mass percentage and pathological ALM/height2 were independently related with severe hepatic steatosis (CAP ≥280 dB/m; OR 1.100, p = 0.011; OR 0.292, p = 0.013, respectively). ROC curve analysis identified specific cut-offs for fat mass percentage (38.65%, area under the curve [AUC] of 0.636) and ALM/height2 index (6.7 kg/m2, AUC of 0.611) for detecting severe liver steatosis. A model combining both cut-offs yielded an AUC of 0.715 (95% C.I. 0.610 – 0.820, p = 0.001). Conclusions In patients with MASLD and T2D, DXA-derived body composition measures may complement conventional anthropometric assessment and help identify individuals with severe hepatic steatosis.

Read PDF

Similar papers

Aug 2026

Association between visceral adiposity index and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes mellitus: an exploratory cross-sectional study.

Higher VAI values are associated with MASLD in patients with T1DM, however, waist circumference outperforms VAI in identifying MASLD, suggesting that VAI may serve as a complementary marker of metabolic dysfunction rather than a standalone screening tool for MASLD in this patient population.

A. Mantovani, I. Milani, R. Morandin et al. · 0 citations
Open access Sep 2026

Association between body composition and metabolic dysfunction-associated steatotic liver disease in Chinese general population: a cross-sectional study stratified by sex and obesity status

FFM/FM ratio shows a universal protective effect against MASLD across sex and obesity strata, while WHR has sex-specific predictive value only in women.

Xia Tan, Xiao-Min Hou, Yuan Wen et al. · 0 citations
Open access Aug 2026

Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease

Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile, and an elevated HSI score, suggesting steatosis, was associated with dyslipidemia, and an elevated NFS score, suggesting fibrosis, was not.

Laura A. M. Konings, Weiwei Xu, Vivian D. de Jong et al. · 0 citations
Open access Sep 2026

Predictors of Hepatic Steatosis and the Limitations of the FIB-4 Index in Type 2 Diabetes: A Cross-Sectional Study

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM). Non-invasive tools (NITs) such as the FIB-4 index, are widely used for risk stratification to identify patients at higher risk of progressive liver disease. This study aim...

Nesreen A. Saadeh, K. Obeidat, Nadeem W. Bani Hani et al. · 0 citations
Open access Aug 2026

DXA-Derived Body Composition Phenotypes in Men with Chronic Hepatitis C

Background: Chronic hepatitis C (CHC) is associated with persistent inflammation, metabolic dysfunction, and body composition abnormalities that extend beyond liver disease. However, the coexistence of reduced muscle mass, occult obesity, and altered fat distribution remains poorly characterized. This study evaluated D...

M. Lazar, C. E. Chiţu, E. Barbu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.